Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00
Provider: Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Valeant Pharmaceuticals International Inc Announces Closing of Public Offering of Common Shares


Monday, 24 Jun 2013 09:22am EDT 

Valeant Pharmaceuticals International Inc announced that the closing of its recently priced public offering (the Offering) of common shares and the exercise in full by the underwriters of their option to purchase additional common shares. The Company issued 23,529,412 common shares at a price of $85.00 per share (the Firm Shares) and, pursuant to the underwriters' exercise of their option to purchase additional common shares, an additional 3,529,412 common shares at a price of $85.00 per share (the Additional Shares), for aggregate gross proceeds of approximately $2.3 billion. The Company intends to use the net proceeds from the Firm Shares sold in the Offering, together with its previously announced debt financing, to fund the consideration of its previously disclosed acquisition (the Merger) of Bausch + Lomb Holdings Incorporated (B+L), the fees and expenses incurred in connection with the Merger; and (the repayment or retirement of B+L's outstanding debt. The Company may use the proceeds from the Additional Shares sold in the Offering, in addition to the manner described above, for general corporate purposes.Goldman, Sachs & Co. will act as sole manager of the Offering outside of Canada and Goldman Sachs Canada Inc. will act as sole manager of the Offering in Canada. 

Company Quote

145.61
-0.45 -0.31%
11:14am EST